Sara A. Hurvitz, MD, discusses outcomes with sacituzumab govitecan-hziy in patients with metastatic triple-negative breast cancer.
Sara A. Hurvitz, MD, director, Breast Cancer Clinical Research Program, co-director, Santa Monica University of California, Los Angeles (UCLA) Outpatient Hematology/Oncology Practice, associate professor of medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, discusses outcomes with sacituzumab govitecan-hziy (Trodelvy) in patients with metastatic triple-negative breast cancer (TNBC).
Results from a prespecified subgroup analysis of the phase 3 ASCENT trial (NCT02574455), which evaluated sacituzumab govitecan vs physician’s choice of single-agent chemotherapy in patients who had received at least 2 lines of chemotherapy for advanced TNBC, found that the agent yielded benefit in all patients, regardless of age, according to Hurvitz. The median progression-free survival (PFS) with sacituzumab govitecan for patients under 65 years of age was 4.6 months vs 1.7 months with chemotherapy. In women 65 years of age or older, the median PFS was 7.1 months vs 2.4 months, respectively.
Notably, there was also an overall survival benefit (OS) with the agent for all patients, regardless of age. Those under the age of 65 years had a median OS of 11.2 months with sacituzumab govitecan vs 6.6 months with chemotherapy. Patients65 years of age or older had a median OS of 15.3 months vs 8.2 months, respectively, Hurvitz explains.
Given these results, older patients should be treated with sacituzumab govitecan if their performance status is adequate, and they are healthy enough to receive systemic therapy, Hurvitz says. Similarly, the objective response rate was also improved with sacituzumab govitecan, regardless of age, Hurvitz concludes.